Investig Clin Urol.  2022 May;63(3):251-261. 10.4111/icu.20210429.

Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis

• Jin Y
• Jung JH
• Han WK
• Hwang EC
• Nho Y
• Lee N
• Yun JE
• Lee KS
• Lee SH
• Lee H
• Yu SY

• KMID: 2529343
• DOI: http://doi.org/10.4111/icu.20210429

Abstract

Purpose
A prostate-specific antigen (PSA) cutoff of 4 ng/mL has been widely used for prostate cancer screening in populationbased settings. However, the accuracy of PSA below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting is inconclusive. We systematically reviewed the accuracy of PSA below 4 ng/mL cutoff in a hospital setting.
Materials and Methods
We systematically reviewed the literature by searching major databases until March 2020, and a metaanalysis and quality assessment were performed.
Results
A total of 11 studies were included at the completion of the screening process. The meta-analysis showed a sensitivity of 0.92 and a specificity of 0.16 for a PSA cutoff below 4 ng/mL. The area under the hierarchical summary receiver operating characteristic curve was 0.87, the positive likelihood ratio was 1.23, the negative likelihood ratio was 0.46, and the diagnostic odds ratio was 2.64. PSA sensitivities and specificities varied according to the cutoff range: 0.94 and 0.17 for 2 to 2.99 ng/mL, and 0.92 and 0.16 for 3 to 3.99 ng/mL, respectively. No significant differences in the sensitivity and specificity of PSA cutoffs in the range of 2 to 2.99 ng/mL and 3 to 3.99 ng/mL were found.
Conclusions
Although a PSA cutoff <3 ng/mL is relatively more sensitive and specific than PSA ≥3 ng/mL, no significant differences in sensitivity and specificity were found in the diagnosis of prostate cancer. Therefore, clinicians should choose an appropriate PSA cutoff on the basis of clinical circumstances and patients’ characteristics.

Keyword

Diagnosis; Prostate-specific antigen; Prostatic neoplasms